| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
8-K: Regulation FD Disclosure; Other Events
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: |
| 16 Nov 2026 | SCHEDULE 13G/A |
| 13 Nov 2026 | SCHEDULE 13G/A |
| 06 Nov 2026 | 10-Q |
| 06 Nov 2026 |
8-K: Results of Operations and Financial Condition
Confirmatory Phase 3 trial of roluperidone (MIN-101C19) ongoing with topline efficacy data expected 2H 2027 |
| 03 Nov 2026 |
Form 4: Kaul Inderjit, Director
Granted 2,328 Stock Option (right to buy) |
| 27 Oct 2026 | SCHEDULE 13G |
| 20 Aug 2026 |
Form 3: Reilly Joseph H., Chief Operating Officer
Holds 20,872 shares of Common Stock |
| 20 Aug 2026 |
Form 3: Aliquo Anthony, Chief Accounting Officer
Holds 1,683 shares of Common Stock |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 13 Aug 2026 | SCHEDULE 13G/A |
| 12 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 07 Aug 2026 | 10-Q |
| 07 Aug 2026 |
8-K: Results of Operations and Financial Condition
Confirmatory Phase 3 trial of roluperidone (MIN-101C19) ongoing with topline efficacy data expected 2H 2027 |
| 03 Aug 2026 |
Form 4: Kaul Inderjit, Director
Granted 12,147 Stock Option (right to buy) |
| 08 Jul 2026 | SCHEDULE 13G/A |
| 05 Jun 2026 |
Form 4: Ahlholm Frederick W, SVP, CFO and Secretary
Granted 680,000 Employee Stock Option (right to buy) |
| 05 Jun 2026 |
Form 4: Luthringer Remy, Director
Granted 1,690,700 Employee Stock Option (right to buy) |
| 05 Jun 2026 |
Form 4: Laghrissi-Thode Fouzia, Director
Granted 50,000 Stock Option (right to buy) |
| 05 Jun 2026 |
Form 4: Kupfer David, Director
Granted 50,000 Stock Option (right to buy) |
Loading...